Clinical Trial of Recombinant Pneumococcal Protein Vaccine

Summary

Streptococcus pneumoniae infections often cause serious health problems, especially in infants and the elderly. Failure to cover all polysaccharide types of vaccines is a greater problem for adults than for children. The purpose of this study was to preliminarily evaluate the safety and immunogenicity of a recombinant pneumococcal protein vaccine applied to adults aged 50 years and older to provide a basis for subsequent clinical trial design.

Timeline

Start

2023-03-11

Primary completion

2023-09-14

Completion

2024-01-30

Drugs

Indications